Wuxi Pharmatech (Cayman) Inc.(WX.NYSE)
Introduction from Google Finance
WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People鈥檚 Republic of China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include the world鈥檚 pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its global customers in shortening the time and lowering the cost of pharmaceutical and medical device R&D by providing outsourcing solutions. WuXi鈥檚 business has been to provide discovery chemistry services to synthesize small molecules at the beginning of the drug discovery process. WuXi conducts all of its business through five operating subsidiaries in People鈥檚 Republic of China and one operating subsidiary in the United States. The Company has two segments: Laboratory services and Manufacturing services segment.
News      more..
Introduction from Company WebSite

Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services from discovery to commercialization. Our services are designed to help our worldwide customers shorten the time and lower the cost of drug and medical device R&D through cost-effective and efficient outsourcing solutions.

We group our operations into two segments:

Laboratory Services
A full range of discovery and development services for pharmaceuticals; development and testing services for biotherapeutics and medical devices; and comprehensive toxicology services. 
Manufacturing Services
Manufacturing services for advanced intermediates and active pharmaceutical ingredients (APIs); cell banking services; and cGMP manufacturing for cellular therapeutics and combination/tissue-based products.
On August 9, 2007, the parent company WuXi PharmaTech (Cayman) Inc. became a New York Stock Exchange listed company and its American Depositary Shares trade under the symbol WX.

Since April 2008, the name of WuXi AppTec's China operations, WuXi PharmaTech Co., Ltd., has been changed to WuXi AppTec Co., Ltd.; and the name of its U.S. operations, AppTec Laboratory Services, Inc., to WuXi AppTec, Inc. 

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号